United Kingdom· GB-APID-3934011000001102
Orimeten 250mg tablets
A aminoglutethimide product containing aminoglutethimide, registered in United Kingdom by Novartis Pharmaceuticals UK Ltd. The same ATC class is registered in 2 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Aminoglutethimide is registered in 2 of 19 countries.
Countries holding a registration under ATC L02BG01 (aminoglutethimide), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 1 of them publish a price we can compare per daily dose
Aminoglutethimide · ATC L02BG01
2 / 19 countries
- Finlandprice
- United Kingdom
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Aminoglutethimide
- Manufacturer
- Novartis Pharmaceuticals UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- L02BG01
- ATC class
- Aminoglutethimide
- Defined daily dose
- 1 g, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
283 interactions on record for aminoglutethimide.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aminoglutethimide · interactions on record
283 records
- 9 severe
- 252 moderate
- 22 minor
Most severe, free to view
- RanolazineC01EB18severe
- AprepitantA04AD12moderate
- RolapitantA04AD14moderate
- NaloxegolA06AH03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aminoglutethimide in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/226d6ad9-ee41-4249-996a-0e5b234bbdb8 GET /v1/drugs/226d6ad9-ee41-4249-996a-0e5b234bbdb8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "3934011000001102",
"desc": "Orimeten 250mg tablets (Novartis Pharmaceuticals UK Ltd)",
"form": "Oral tablet",
"vpid": "42080411000001107",
"source": "dmd",
"vtm_id": "774547005",
"strength": "250 mg",
"substance": "Aminoglutethimide",
"ingredient": "Aminoglutethimide",
"supplier_code": "2920101000001102"
}See everything about aminoglutethimide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.